Analysis of infections and malignancy risks among patients with myasthenia gravis compared with matched controls in a US real-world setting
Journal of Neuromuscular Diseases · 2026
DOI: 10.1177/22143602251403092 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Neuromuscular Diseases, 2026. Verfasst von Jana Podhorna und 7 weiteren Autor:innen. Beteiligte Einrichtung: argenx, Ghent, Belgium. Hauptthemen laut MEDLINE: Myasthenia Gravis, Neoplasms, Opportunistic Infections, Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Argenx.
Abstract (Originalsprache)
Introduction
Myasthenia gravis (MG) is a rare, debilitating autoimmune disease associated with pathogenic immunoglobulin G autoantibodies directed against components of the neuromuscular junction. The autoimmune nature of the disease and long-term immunosuppressive treatment may increase susceptibility to infections and malignancies, but studies investigating the association between MG and infections or malignancies remain scarce.
Methods
We conducted a retrospective, observational study using Optum's deidentified Market Clarity Data (Market Clarity) to evaluate the incidence rate (IR) of infections and malignancies in US-based patients with MG in a real-world setting. Adults with ≥2 diagnosis claims of MG were identified over a 2-year period (2016–2019) and propensity score (PS) matched with controls from the general population without MG. Patients with malignancies in the 1-year look-back period were excluded.
Results
Patients with MG (N = 5002) were compared with the PS-matched general population (N = 20,008). The IR of serious infections (primary outcome) was higher in the MG cohort compared with the general population (52.81 vs 31.46 per 1000 person-years [PY], respectively). IRs of opportunistic infections (87.48 vs 57.01 per 1000 PY) and infection-related death (3.98 vs 1.94 per 1000 PY) were also higher in the MG cohort compared with the general population. The overall rate of malignancy was higher in the MG cohort compared with the general population (73.55 vs 50.01 per 1000 PY, respectively).
Conclusions
In this analysis, patients with MG were more susceptible to serious infections, infection-related death, and malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- argenx, Ghent, Belgium.
- ZS Associates, Evanston, Illinois, USA.
- Columbia University, New York, New York, USA.
- Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Neurology, Ruhr University Bochum, BG University Hospital Bergmannsheil, Bochum, Germany.
- BG University Hospital Bergmannsheil, Heimer Institute for Muscle Research, Bochum, Germany.
ORCID-Profile: Kushal B Naik, Yuebing Li
Förderung
- Argenx
Zitieren
APA
Podhorna, J., Ward, C., Naik, K. B., Lee, I., Li, Y., Ruck, T., Teperov, E., & Guptill, J. T. (2026). Analysis of infections and malignancy risks among patients with myasthenia gravis compared with matched controls in a US real-world setting. Journal of Neuromuscular Diseases. https://doi.org/10.1177/22143602251403092
Vancouver
Podhorna J, Ward C, Naik KB, Lee I, Li Y, Ruck T, et al. Analysis of infections and malignancy risks among patients with myasthenia gravis compared with matched controls in a US real-world setting. Journal of Neuromuscular Diseases. 2026. doi:10.1177/22143602251403092
BibTeX
@article{Podhorna2026,
author = {Podhorna, Jana and Ward, Charlotte and Naik, Kushal B and Lee, Ikjae and Li, Yuebing and Ruck, Tobias and Teperov, Elizabeth and Guptill, Jeffrey T},
title = {Analysis of infections and malignancy risks among patients with myasthenia gravis compared with matched controls in a US real-world setting},
journal = {Journal of Neuromuscular Diseases},
year = {2026},
doi = {10.1177/22143602251403092}
}
EUVIMED